Clinical molecular imaging and in particular Positron Emission Tomography (PET) is becoming increasingly important in medicine. Together with biological investigation, it actively participates in improving diagnosis, in defining the most appropriate treatments and in evaluating their therapeutic efficacy for each patient. Its applications notably target the major public health fields, namely oncology, neurology and cardiovascular diseases.

However, the enormous potential of this technology is not currently sufficiently exploited in clinical practice due to technical, logistical, organizational and economic constraints as well as the regulatory complexity of their implementation.

The goal of the Nancyclotep platform is to remove the barriers that limit the use of these techniques in current medical practice and thereby meet the needs of patients, of the health system and of industrial R&D as well as of academic research.

In 2007, owing to the willingness and investment support of the local authorities in Lorraine, the EIG Nancyclotep was created with the aim of implementing and operating a preclinical and clinical research and development structure in the field of Positron Emission Tomography.

This EIG currently consists of three members: the University Hospital of Nancy (CHRU), the University of Lorraine and the Posifit company.